NASDAQ$IRD
Opus Genetics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Ocuphire announced financial results for the second quarter of 2021 and provided a corporate update.
Ocuphire Pharma reported a productive second quarter of 2021, marked by clinical trial successes, key data presentations, and strengthened IP protection for Nyxol. The company's cash balance reached $24.2 million, expected to provide runway into late 2022.
- Announced positive top-line results from VEGA-1 Phase 2 trial of Nyxol plus low-dose pilocarpine (LDP) for presbyopia.
- Initiated the ZETA-1 Phase 2 clinical trial to evaluate oral APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR).
- Closed a $15 million registered direct offering and just over $4 million from ATM, extending cash runway into late 2022.
- Received two new U.S. patent grants covering Nyxol® including Nyxol plus LDP claims for the treatment of presbyopia through 2039.
Headline financials
Revenue & EPS history
Ocuphire · Revenue · Quarterly
$100K
Revenue by segment
Ocuphire · $100K total across 1 segment · Q2 2021
- Collaboration Revenue$100K—100.0%
Forward guidance
Ocuphire anticipates several key milestones in 2022, including initiating Phase 3 programs for Presbyopia (VEGA-2/3) and completing enrollment in the Phase 3 trial for Night Vision Disturbances (LYNX-1). They also plan to file NDA submission with FDA for Nyxol in RM indication in late 2022.
Tailwinds
- Initiate second Phase 3 (MIRA-3) registration trial and a small pediatric trial (MIRA-4) in the second half of 2021 investigating Nyxol with results expected in early 2022 for Reversal of Mydriasis (RM).
- Planning to file NDA submission with FDA for Nyxol in RM indication in late 2022.
- Initiate Phase 3 program (VEGA-2/3) in first half of 2022 investigating Nyxol and LDP for Presbyopia.
- Completion of enrollment expected by year-end 2021 and top-line data expected in early 2022 from Phase 3 (LYNX-1) registration trial investigating Nyxol for Night Vision Disturbances.
- Completion of enrollment in Phase 2 (ZETA-1) trial investigating APX3330 and top-line data expected in 2022 for Diabetic Retinopathy and Diabetic Macular Edema.
Headwinds
- Success of clinical trials is subject to regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts.
- Clinical trials are subject to regulatory requirements or developments.
- Clinical trials are subject to changes to clinical trial designs and regulatory pathways.
- The company's cash runway is dependent on changes in capital resource requirements and the inability of Ocuphire to obtain sufficient additional capital.
- Commercialization of any of Ocuphire’s product candidates is subject to legislative, regulatory, political and economic developments, changes in market opportunities, and the effects of COVID-19.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-3.6%
Avg return
Earnings day
-3.8%
Avg return
5 days after
-3.7%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+16.7%
Q1 2017
Best reaction
-47.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -6.1% | -23.7% | |
| Q4 2025 | +1.7% | +5.5% | +15.3% | |
| Q3 2025 | -3.1% | -11.7% | +19.8% | |
| Q2 2025 | +7.4% | +0.9% | +25.5% | |
| Q1 2025 | +7.5% | +4.2% | +2.1% | |
| Q3 2024 | -7.7% | -9.4% | -5.1% | |
| Q2 2024 | -24.7% | -19.9% | -24.1% | |
| Q1 2024 | -14.3% | -11.7% | -13.8% | |
| Q4 2023 | -12.2% | -13.9% | -19.7% | |
| Q3 2023 | +13.4% | +3.5% | -4.9% | |
| Q2 2023 | +0.5% | +0.7% | -3.1% | |
| Q1 2023 | -18.9% | -28.0% | -36.0% | |
| Q4 2022 | +4.2% | +44.2% | +42.5% | |
| Q3 2022 | -2.8% | +13.1% | +52.3% | |
| Q2 2022 | -9.7% | -6.1% | -14.3% | |
| Q1 2022 | +8.5% | +6.5% | +5.5% | |
| Q4 2021 | +11.1% | -9.9% | -35.9% | |
| Q3 2021 | -0.3% | -10.9% | -5.6% | |
| Q2 2021 | -8.5% | -14.7% | -0.6% | |
| Q1 2021 | -7.8% | -5.9% | +17.4% | |
| Q4 2020 | -12.7% | -7.8% | -34.7% | |
| Q3 2020 | +1.4% | -10.8% | -22.4% | |
| Q2 2020 | -1.6% | +1.2% | -25.9% | |
| Q1 2020 | -16.4% | -2.7% | +3.8% | |
| Q3 2019 | -5.9% | -9.3% | -11.2% | |
| Q2 2019 | -47.3% | -49.3% | -54.8% | |
| Q1 2019 | -10.4% | -11.0% | -10.3% | |
| Q2 2018 | +2.7% | +5.4% | +17.0% | |
| Q4 2018 | -2.9% | -3.5% | -4.7% | |
| Q3 2017 | +4.9% | +6.5% | +15.7% | |
| Q2 2017 | +5.9% | -1.6% | +26.5% | |
| Q1 2017 | +16.7% | +29.2% | -10.4% | |
| Q2 2016 | +0.0% | -3.7% | -3.7% | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro